ResearcherMassachusetts General HospitalActive in the last 2 years

Alexander Armstrong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-6957-9903; OpenAlex author ID A5102475231. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 1 paper

Papers 1

Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-2907 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Giulia Escobar · 1 shared paper, 2026 · strength 0.25
- Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907 ↗
Sangwoo Park · 1 shared paper, 2026 · strength 0.25
- Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907 ↗
Marcela Valderrama Maus · 1 shared paper, 2026 · strength 0.25
- Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907 ↗
Diego Salas‐Benito · 1 shared paper, 2026 · strength 0.25
- Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.